Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$673.80 +0.5%	$571.11	$475.65 ▼ $689.13	$41.02B	0.39	414,608 shs	633,642 shs
BIOVF Swedish Orphan Biovitrum	$29.79	$29.92	$24.08 ▼ $32.25	$10.61B	0.46	65 shs	N/A
BNTX BioNTech	$107.34 -0.1%	$108.11	$76.53 ▼ $131.49	$25.84B	1.23	598,465 shs	840,683 shs
RPRX Royalty Pharma	$37.11 +0.8%	$35.21	$24.05 ▼ $37.56	$20.69B	0.55	2.65 million shs	1.88 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	+0.52%	+13.82%	+23.61%	+3.71%	+30.61%
BIOVF Swedish Orphan Biovitrum	0.00%	0.00%	+1.85%	-2.33%	+9.48%
BNTX BioNTech	-0.15%	-6.91%	-0.85%	+2.29%	+24.52%
RPRX Royalty Pharma	+0.84%	+1.20%	+2.54%	+12.83%	+31.74%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARGX argenex	2.8337 of 5 stars	2.5	4.0	0.0	0.0	2.5	1.7	1.9
BIOVF Swedish Orphan Biovitrum	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BNTX BioNTech	2.7484 of 5 stars	4.4	3.0	0.0	0.0	2.1	0.8	0.0
RPRX Royalty Pharma	4.9176 of 5 stars	3.6	3.0	3.3	3.7	3.5	1.7	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenex	3.10	Buy	$736.81	9.35% Upside
BIOVF Swedish Orphan Biovitrum	4.00	Strong Buy	N/A	N/A
BNTX BioNTech	2.76	Moderate Buy	$136.58	27.24% Upside
RPRX Royalty Pharma	3.25	Buy	$49.00	32.04% Upside

Current Analyst Ratings Breakdown

Latest BIOVF, ARGX, BNTX, and RPRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/1/2025	ARGX argenex	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$700.00 ➝ $766.00
8/1/2025	ARGX argenex	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$1,060.00 ➝ $1,070.00
8/1/2025	ARGX argenex	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$720.00 ➝ $774.00
7/31/2025	ARGX argenex	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$741.00 ➝ $756.00
7/22/2025	RPRX Royalty Pharma	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $42.00
7/21/2025	ARGX argenex	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$715.00
7/16/2025	BNTX BioNTech	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$127.00 ➝ $126.00
7/10/2025	RPRX Royalty Pharma	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$51.00 ➝ $54.00
7/10/2025	BNTX BioNTech	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$132.00 ➝ $133.00
7/8/2025	ARGX argenex	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy
7/3/2025	ARGX argenex	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$700.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenex	$2.25B	18.31	$2.99 per share	225.66	$90.49 per share	7.45
BIOVF Swedish Orphan Biovitrum	$2.46B	4.31	$2.05 per share	14.52	$11.36 per share	2.62
BNTX BioNTech	$2.98B	8.67	N/A	N/A	$87.61 per share	1.23
RPRX Royalty Pharma	$2.26B	9.22	$4.23 per share	8.77	$17.56 per share	2.11

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenex	$833.04M	$16.21	34.55	62.10	1.20	40.98%	33.30%	29.52%	N/A
BIOVF Swedish Orphan Biovitrum	$367.52M	$1.19	25.03	∞	N/A	16.05%	11.67%	6.34%	N/A
BNTX BioNTech	-$719.92M	-$3.40	N/A	N/A	N/A	-27.37%	-3.94%	-3.41%	8/4/2025 (Estimated)
RPRX Royalty Pharma	$858.98M	$1.85	20.06	7.64	2.45	48.23%	24.71%	13.87%	8/6/2025 (Estimated)

Latest BIOVF, ARGX, BNTX, and RPRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	RPRX Royalty Pharma	$1.10	N/A	N/A	N/A	$750.06 million	N/A
8/4/2025	Q2 2025	BNTX BioNTech	-$1.38	N/A	N/A	N/A	$161.26 million	N/A
7/31/2025	Q2 2025	ARGX argenex	$2.84	$3.74	+$0.90	$3.74	$776.82 million	$866.79 million
7/16/2025	Q2 2025	BIOVF Swedish Orphan Biovitrum	$0.18	$0.24	+$0.06	$0.19	$644.68 million	$649.61 million
5/8/2025	Q1 2025	ARGX argenex	$2.32	$2.58	+$0.26	$2.58	$748.34 million	$1.35 billion
5/8/2025	Q1 2025	RPRX Royalty Pharma	$0.99	$1.06	+$0.07	$0.41	$724.69 million	$839.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenex	N/A	N/A	N/A	N/A	N/A
BIOVF Swedish Orphan Biovitrum	N/A	N/A	N/A	N/A	N/A
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
RPRX Royalty Pharma	$0.88	2.37%	N/A	47.57%	5 Years

Latest BIOVF, ARGX, BNTX, and RPRX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/18/2025	RPRX Royalty Pharma	quarterly	$0.22	2.48%	8/15/2025	8/15/2025	9/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenex	N/A	7.29	6.68
BIOVF Swedish Orphan Biovitrum	0.22	1.00	0.66
BNTX BioNTech	0.01	10.18	10.02
RPRX Royalty Pharma	0.68	1.56	1.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenex	60.32%
BIOVF Swedish Orphan Biovitrum	N/A
BNTX BioNTech	15.52%
RPRX Royalty Pharma	54.35%

Insider Ownership

Company	Insider Ownership
ARGX argenex	2.43%
BIOVF Swedish Orphan Biovitrum	N/A
BNTX BioNTech	19.20%
RPRX Royalty Pharma	18.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenex	1,599	61.20 million	59.71 million	Optionable
BIOVF Swedish Orphan Biovitrum	1,772	356.00 million	N/A	Not Optionable
BNTX BioNTech	6,772	240.39 million	194.24 million	Optionable
RPRX Royalty Pharma	80	562.24 million	455.98 million	Optionable

BIOVF, ARGX, BNTX, and RPRX Headlines

Recent News About These Companies

XTX Topco Ltd Takes $1.65 Million Position in Royalty Pharma PLC (NASDAQ:RPRX)

August 2 at 5:21 AM | marketbeat.com

Mackenzie Financial Corp Increases Stock Holdings in Royalty Pharma PLC (NASDAQ:RPRX)

August 2 at 5:12 AM | marketbeat.com

Royalty Pharma PLC (NASDAQ:RPRX) Shares Sold by Zurcher Kantonalbank Zurich Cantonalbank

August 2 at 5:01 AM | marketbeat.com

Royalty Pharma PLC (NASDAQ:RPRX) is Torray Investment Partners LLC's Largest Position

August 1 at 6:17 AM | marketbeat.com

Eastern Bank Sells 28,871 Shares of Royalty Pharma PLC (NASDAQ:RPRX)

August 1 at 5:41 AM | marketbeat.com

Royalty Pharma (RPRX) to Release Quarterly Earnings on Wednesday

July 31 at 10:48 AM | marketbeat.com

Y Intercept Hong Kong Ltd Acquires New Shares in Royalty Pharma PLC (NASDAQ:RPRX)

July 31 at 4:41 AM | marketbeat.com

2 Reasons to Watch RPRX and 1 to Stay Cautious

July 30 at 12:22 AM | msn.com

Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?

July 30 at 11:06 AM | zacks.com

Pacific Capital Partners Ltd Takes Position in Royalty Pharma PLC (NASDAQ:RPRX)

July 30 at 5:37 AM | marketbeat.com

Ridgewood Investments LLC Sells 11,087 Shares of Royalty Pharma PLC (NASDAQ:RPRX)

July 28, 2025 | marketbeat.com

Mediolanum International Funds Ltd Sells 8,894 Shares of Royalty Pharma PLC (NASDAQ:RPRX)

July 28, 2025 | marketbeat.com

Allianz Asset Management GmbH Has $6.03 Million Stock Holdings in Royalty Pharma PLC (NASDAQ:RPRX)

July 28, 2025 | marketbeat.com

Envestnet Asset Management Inc. Boosts Position in Royalty Pharma PLC (NASDAQ:RPRX)

July 28, 2025 | marketbeat.com

If EPS Growth Is Important To You, Royalty Pharma (NASDAQ:RPRX) Presents An Opportunity

July 26, 2025 | finance.yahoo.com

Royalty Pharma (NASDAQ:RPRX) Sets New 12-Month High - Here's What Happened

July 26, 2025 | marketbeat.com

Baillie Gifford & Co. Lowers Stock Holdings in Royalty Pharma PLC (NASDAQ:RPRX)

July 26, 2025 | marketbeat.com

Royalty Pharma plc (RPRX) Stock Dividend Growth Grade & History ...

July 24, 2025 | seekingalpha.com

Winners And Losers Of Q1: Zoetis (NYSE:ZTS) Vs The Rest Of The Branded Pharmaceuticals Stocks

July 24, 2025 | msn.com

Cwm LLC Has $642,000 Stock Position in Royalty Pharma PLC (NASDAQ:RPRX)

July 24, 2025 | marketbeat.com

Vestor Capital LLC Buys New Shares in Royalty Pharma PLC (NASDAQ:RPRX)

July 23, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIOVF, ARGX, BNTX, and RPRX Company Descriptions

argenex NASDAQ:ARGX

$673.80 +3.47 (+0.52%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$673.88 +0.09 (+0.01%)

As of 08/1/2025 04:32 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Swedish Orphan Biovitrum OTCMKTS:BIOVF

$29.79 0.00 (0.00%)

As of 08/1/2025

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Sanofi, Apellis Pharmaceuticals Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.

BioNTech NASDAQ:BNTX

$107.34 -0.16 (-0.15%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$107.38 +0.03 (+0.03%)

As of 08/1/2025 07:39 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Royalty Pharma NASDAQ:RPRX

$37.11 +0.31 (+0.84%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$37.47 +0.36 (+0.97%)

As of 08/1/2025 07:33 PM Eastern

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time